Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
暂无分享,去创建一个
Chris Bailey-Kellogg | Jaranit Kaewkungwal | Todd J. Suscovich | Galit Alter | Robert J. O'Connell | Merlin L. Robb | Margaret E. Ackerman | Ickwon Choi | Amy W. Chung | Supachai Rerks-Ngarm | Punnee Pitisuttithum | Sorachai Nitayaphan | Donald Francis | Nelson Michael | Jerome H. Kim | Jerome H. Kim | C. Bailey-Kellogg | M. Robb | G. Alter | S. Rerks-Ngarm | P. Pitisuttithum | S. Nitayaphan | J. Kaewkungwal | D. Francis | N. Michael | M. Ackerman | R. O'Connell | T. Suscovich | Ickwon Choi | A. Chung | R. O’Connell
[1] J. Mascola,et al. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.
[2] J. Margolick,et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. , 1996, Journal of immunology.
[3] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[4] Saravudh Suvannadabba,et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.
[5] G. Carrasquilla,et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.
[6] Carl E. Rasmussen,et al. In Advances in Neural Information Processing Systems , 2011 .
[7] C. Bailey-Kellogg,et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.
[8] Corinna Cortes,et al. Support-Vector Networks , 1995, Machine Learning.
[9] S. Plotkin. Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.
[10] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[11] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[12] Tomer Hertz,et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.
[13] Guido Ferrari,et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.
[14] R. Haubrich,et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. , 1999, The Journal of infectious diseases.
[15] D. Venzon,et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.
[16] Punnee Pitisuttithum,et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.
[17] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[19] Malika Charrad,et al. NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set , 2014 .
[20] Robin A. Weiss,et al. Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.
[21] R. Tibshirani,et al. Least angle regression , 2004, math/0406456.
[22] S. Kent,et al. Activation of NK Cells by ADCC Antibodies and HIV Disease Progression , 2011, Journal of acquired immune deficiency syndromes.
[23] D. Irvine,et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.
[24] J. H. Ward. Hierarchical Grouping to Optimize an Objective Function , 1963 .
[25] Gary J. Nabel,et al. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.
[26] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[27] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[28] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[29] Jerome H. Kim,et al. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.
[30] J. Goeman. L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.
[31] Bernhard Schölkopf,et al. New Support Vector Algorithms , 2000, Neural Computation.
[32] Jerome H. Kim,et al. Machine Learning Methods Enable Predictive Modeling of Antibody Feature : Function Relationships in RV 144 Vaccinees , 2015 .
[33] G. Alter,et al. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. , 2012, Annual review of medicine.
[34] Alexander J. Smola,et al. Support Vector Regression Machines , 1996, NIPS.
[35] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[36] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[37] C. Bailey-Kellogg,et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. , 2013, The Journal of clinical investigation.
[38] George C. Runger,et al. Feature selection via regularized trees , 2012, The 2012 International Joint Conference on Neural Networks (IJCNN).
[39] P. Bruhns. Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.